drugset

drugset / Trial / NCT00504829

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829 ↗

Phase 2 Completed 220 enrolled Veloxis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

The current study is designed to test the efficacy, safety and tolerability of LCP-AtorFen, a combination of atorvastatin and fenofibrate.

Timeline

Start: 2007-07
Primary completion: 2008-02
Completion: 2008-07

Publications

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	40 mg	—
Subject	Fenofibrate	Small molecule	100 mg	—
Subject	Fenofibrate	Small molecule	145 mg	—

Indications